Form 4: BioLargo CSO Acquires Shares, Boosts Stake

BioLargo's Chief Science Officer, Kenneth Reay Code, acquired 54,803 shares of common stock at $0.1843 per share, increasing his beneficial ownership.

Summary

• Kenneth Reay Code, BioLargo, Inc.'s Director, 10% Owner, and Chief Science Officer, acquired 54,803 shares of common stock.
• The transaction occurred on December 31, 2025, at an acquisition price of $0.1843 per share.
• Shares were received from BioLargo in exchange for a reduction in amounts owed to Mr. Code for salary and unreimbursed business expenses.
• The acquired shares are subject to a Lock-Up Agreement, restricting their sale until BioLargo reports gross revenue of at least $40 million on a consolidated basis for any reported period, or its market capitalization exceeds $300 million, or there is a 'change in control' in the Issuer.
• Following this transaction, Mr. Code beneficially owns an aggregate of 25,806,308 shares, which includes 22,139,012 shares owned indirectly through a wholly-owned corporation.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key insider, especially through the conversion of debt, generally signals strong confidence in the company's future. However, the significant performance-based lock-up conditions introduce a degree of uncertainty regarding the company's ability to meet these ambitious targets.

Positives

• An insider, the Chief Science Officer, acquired additional shares, signaling confidence in the company's future.
• The acquisition was made by converting salary and unreimbursed business expenses into equity, which reduces the company's liabilities and demonstrates the officer's commitment.

Negatives

• The shares are subject to a lock-up agreement with significant performance-based release conditions (e.g., $40 million in gross revenue or $300 million market capitalization), indicating substantial hurdles for future liquidity of these shares.

Risks

• The lock-up agreement on the acquired shares ties their liquidity to the achievement of specific financial milestones ($40 million gross revenue or $300 million market capitalization), which may not be met in the near term.
• Failure to meet the conditions of the lock-up agreement could impact the reporting person's ability to monetize these shares.

Future Outlook

The lock-up agreement on the acquired shares implies a future outlook focused on achieving significant growth targets, specifically reaching $40 million in consolidated gross revenue or a market capitalization exceeding $300 million, before the shares can be freely sold.

Industry Context

Insider buying, particularly when an officer converts owed compensation into equity, is often viewed by the market as a positive signal, indicating management's belief in the company's long-term prospects and a willingness to align their personal financial interests with those of shareholders. This action can be interpreted as a vote of confidence in BioLargo's future growth and strategic direction.

Corporate Governance

Related Party Transactions

• Kenneth Reay Code, an officer and director of BioLargo, Inc., acquired 54,803 shares of common stock from the company in exchange for a reduction in amounts owed to him for salary and unreimbursed business expenses. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The insider acquisition by a key officer may be perceived as a positive signal, potentially boosting investor confidence in the company's future prospects.
• Creditors (specifically Kenneth Reay Code): Mr. Code converted his outstanding salary and expense claims into equity, demonstrating a long-term commitment to the company and reducing the company's short-term liabilities to him.

Next Steps

• BioLargo, Inc. will need to achieve consolidated gross revenue of at least $40 million for any reported period, or its market capitalization must exceed $300 million, or a 'change in control' must occur for the acquired shares to be released from the lock-up agreement.

Key Dates

Keywords

BioLargo, BLGO, SEC Form 4, insider trading, stock acquisition, Chief Science Officer, common stock, beneficial ownership, lock-up agreement, debt conversion, equity compensation